Your browser doesn't support javascript.
loading
Status of research on natural protein tyrosine phosphatase 1B inhibitors as potential antidiabetic agents: Update.
Liu, Zhenyang; Gao, Hongwei; Zhao, Ziyu; Huang, Mengrui; Wang, Shengnan; Zhan, Jiuyu.
Affiliation
  • Liu Z; School of Life Science, Ludong University, Yantai, Shandong 264025, China.
  • Gao H; School of Life Science, Ludong University, Yantai, Shandong 264025, China. Electronic address: gaohongw369@ldu.edu.cn.
  • Zhao Z; School of Life Science, Ludong University, Yantai, Shandong 264025, China.
  • Huang M; School of Life Science, Ludong University, Yantai, Shandong 264025, China.
  • Wang S; School of Life Science, Ludong University, Yantai, Shandong 264025, China.
  • Zhan J; School of Life Science, Ludong University, Yantai, Shandong 264025, China. Electronic address: zhanjy@ldu.edu.cn.
Biomed Pharmacother ; 157: 113990, 2023 Jan.
Article de En | MEDLINE | ID: mdl-36459712
ABSTRACT
Protein tyrosine phosphatase 1B (PTP1B) is a crucial therapeutic target for multiple human diseases comprising type 2 diabetes (T2DM) and obesity because it is a seminal part of a negative regulator in both insulin and leptin signaling pathways. PTP1B inhibitors increase insulin receptor sensitivity and have the ability to cure insulin resistance-related diseases. However, the few PTP1B inhibitors that entered the clinic (Ertiprotafib, ISIS-113715, Trodusquemine, and JTT-551) were discontinued due to side effects or low selectivity. Molecules with broad chemical diversity extracted from natural products have been reported to be potent PTP1B inhibitors with few side effects. This article summarizes the recent PTP1B inhibitors extracted from natural products, clarifying the current research progress, and providing new options for designing new and effective PTP1B inhibitors.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Produits biologiques / Insulinorésistance / Diabète de type 2 Limites: Humans Langue: En Journal: Biomed Pharmacother Année: 2023 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Produits biologiques / Insulinorésistance / Diabète de type 2 Limites: Humans Langue: En Journal: Biomed Pharmacother Année: 2023 Type de document: Article Pays d'affiliation: Chine